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Abstract
Background: Characterization of abdominal and intra-abdominal fat requires imaging, and thus is not feasible in large
epidemiologic studies.
Objective: We investigated whether biomarkers may complement anthropometry (body mass index [BMI], waist
circumference [WC], and waist-hip ratio [WHR]) in predicting the size of the body fat compartments by analyzing blood
biomarkers, including adipocytokines, insulin resistance markers, sex steroid hormones, lipids, liver enzymes and gastro-
neuropeptides.
Methods: Fasting levels of 58 blood markers were analyzed in 60 healthy, Caucasian or Japanese American postmenopausal
women who underwent anthropometric measurements, dual energy X-ray absorptiometry (DXA), and abdominal magnetic
resonance imaging. Total, abdominal, visceral and hepatic adiposity were predicted based on anthropometry and the
biomarkers using Random Forest models.
Results: Total body fat was well predicted by anthropometry alone (R2 = 0.85), by the 5 best predictors from the biomarker
model alone (leptin, leptin-adiponectin ratio [LAR], free estradiol, plasminogen activator inhibitor-1 [PAI1], alanine
transaminase [ALT]; R2 = 0.69), or by combining these 5 biomarkers with anthropometry (R2 = 0.91). Abdominal adiposity
(DXA trunk-to-periphery fat ratio) was better predicted by combining the two types of predictors (R2 = 0.58) than by
anthropometry alone (R2 = 0.53) or the 5 best biomarkers alone (25(OH)-vitamin D3, insulin-like growth factor binding
protein-1 [IGFBP1], uric acid, soluble leptin receptor [sLEPR], Coenzyme Q10; R2 = 0.35). Similarly, visceral fat was slightly
better predicted by combining the predictors (R2 = 0.68) than by anthropometry alone (R2 = 0.65) or the 5 best biomarker
predictors alone (leptin, C-reactive protein [CRP], LAR, lycopene, vitamin D3; R
2 = 0.58). Percent liver fat was predicted better
by the 5 best biomarker predictors (insulin, sex hormone binding globulin [SHBG], LAR, alpha-tocopherol, PAI1; R2 = 0.42) or
by combining the predictors (R2 = 0.44) than by anthropometry alone (R2 = 0.29).
Conclusion: The predictive ability of anthropometry for body fat distribution may be enhanced by measuring a small
number of biomarkers. Studies to replicate these data in men and other ethnic groups are warranted.
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Introduction
Excess body fat leads to changes in a number of biological
pathways. In particular, fat accumulation in the abdominal, intra-
abdominal (or visceral) and hepatic depots has been associated
with elevated risk of metabolic diseases [1–4]. Although fat
distribution can be assessed by using dual energy X-ray
absorptiometry (DXA) for total and regional fat composition,
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and using computed tomography (CT) or magnetic resonance
imaging (MRI) scans for visceral and hepatic fat distribution, it is
rarely feasible to utilize these costly imaging methods in large-scale
population studies. Anthropometric measures, such as body mass
index (BMI) and waist size (waist circumference [WC] or waist-hip
ratio [WHR]), have been used as surrogates for total and
abdominal adiposity: however, their correlations with fat mass
vary by sex, ethnicity, life stages and other as yet-unknown factors
[5,6], indicating the limitations of these proxies, particularly for
heterogeneous populations when studying disease risks. Moreover,
these anthropometric measurements are poorly correlated with fat
compartments that carry the highest metabolic risk, such as
visceral and hepatic fat [6,7]. In this regard, judiciously selected
biomarkers assessed in peripheral blood may provide an attractive
alternative to, or complement, anthropometry as predictors of
body fat composition and distribution.
Few systematic attempts have been made to predict adiposity
using a comprehensive array of biomarkers [8]. One major
challenge is the limitation of conventional statistical methods to
handle a large number of correlated predictors without over-fitting
the data and leading to unreliable predictive ability [9]. The recent
increase in computing capacity has allowed the development of
statistical methods based on re-sampling to predict complex traits
from large numbers of independent markers in a limited sample
size, such as Random Forest modeling. In this report, we present a
Random Forest analysis of commonly used anthropometric
measures and circulating biochemical markers for the prediction
of total and compartment-specific body fat content among healthy,
Caucasian or Japanese American postmenopausal women. Our
general objective was to determine the best predictive biomarkers
for each body fat measure to complement the anthropometric
indicators. We studied biochemical markers of inflammation,
insulin resistance, sex steroid hormones, lipids, liver function, and
gastro-neuropeptides, which have been associated with body fat
distribution in past reports. Our findings demonstrate that
measuring a small subset of these known biomarkers enhanced
the prediction ability of simple anthropometric indicators for total
and abdominal adiposity, but especially for visceral and hepatic
adiposity in these two female populations.
Subjects and Methods
Study Subjects
As described previously [10,11], study subjects were recruited
from a random sample (n = 218) of participants in the Multiethnic
Cohort Study [12] who were female residents of Oahu, Hawaii,
were 60–65 years of age as of September 2009, and had BMIs in
the range of 18.5–40 kg/m2. All reported that both of their
parents were either of Caucasian or Japanese ethnicity. Exclusion
criteria included current smoking, use of selected medications
(chemotherapy, insulin, or weight-loss drugs), a substantial weight
change ($ 20 pounds in the past six months) or soft or metal
implants/objects in the body (n= 46). An additional 98 women
were unavailable or unwilling to participate. Among the 74
remaining eligible women, we selected 60 women (30 Caucasians
and 30 Japanese Americans) distributed equally across BMI
categories (cutoff points at BMI 22, 25, 27.5, and 30 kg/m2) to
obtain a balanced representation by ethnicity and BMI levels.
Participants underwent anthropometric measurements, a DXA
scan and a fasting venous blood collection at the University of
Hawaii Clinical Research Center (UH-CRC). Forty-eight of the
60 women (28 Caucasian and 20 Japanese American) also agreed
to participate in an MRI scan at the University of Hawaii and
Queen’s Medical Center (UH-QMC) MR Research Center. The
Institutional Review Boards of UH and QMC approved the study
protocol, and all participants signed an informed consent.
Body Fat Composition and Distribution
Anthropometric measurements included standing and sitting
heights, weight, and waist and hip circumferences. Waist
circumference (WC) was measured at two locations, at the navel
and immediately above iliac crest, and hip circumference (HC)
was measured at the widest area between waist and thighs,
including buttocks [13]. WC at navel and its ratio over HC (waist-
hip ratio; WHR) were used in the current analysis. A whole-body
DXA scan (GE Lunar Prodigy, Madison, WI) was performed to
measure total and regional body fat mass in the trunk, arms and
legs. Trunk fat-periphery fat ratio (TPFR), calculated by dividing
the trunk fat mass by the sum of fat mass in the arms and legs, was
used as an indicator of abdominal adiposity. A subset of women
completed an abdominal MRI scan on a 3 Tesla TIM Trio
scanner (Siemens Medical Systems, Erlangen, Germany) in a
supine position with a series of water-suppressed lipid scans at L4–
L5 inter-vertebral position and axial triple gradient-echo scans of
the liver [10]. Using the NIH program, Image J (http://rsbweb.
nih.gov/ij), each subject’s cross-sectional lipid MR image was
analyzed to determine the total fat and visceral fat areas at L4–L5
and to estimate the subcutaneous fat area by subtraction. Using a
Siemens Leonardo workstation, the relative fat content of the liver
was calculated based on the signal intensities of the three gradient
echo images from a circular region (15–25 cm2) in the lateral
portion of the right lobe [14].
Circulatory Biochemical Markers
Serum and plasma components were separated from fasting
blood samples and stored in aliquots at280uC until analysis at the
University of Hawaii Cancer Center’s (UHCC) Analytical
Laboratory Shared Resource. The 58 analytes measured and
their analytic methods, along with information on commercial kits
when applicable, are listed in Table S1 (Supporting Infor-
mation). Some of the markers were derived from directly
measured analytes, as indicated in the Table. All assays were
conducted on the same day in one or two batches, with most
markers showing 2–20% variation among blind duplicate QC
samples (10% of study samples; Table S1). Accuracy was assured
by participation in quality assurance programs by the National
Institute for Standards and Technology (Gaithersburg, MD) and/
or by the testing of commercial control samples.
Statistical Analysis
We applied a Classification and Regression Tree (CART)-based
method called Random Forest in order to predict each of the
adiposity measurements of interest (total adiposity [total fat mass],
abdominal adiposity [TPFR, visceral adiposity [visceral fat area at
L4–L5] and hepatic adiposity [percent liver fat] from a large
number of predictors (anthropometry, key descriptive covariates,
and biomarkers) in a limited sample of women. Random Forest
takes an ensemble approach to create and summarize multiple
regression trees, which improves the prediction accuracy com-
pared to conventional CART methods [15–17]. Using a subset of
all available predictors and a random bootstrap subsample of all
women, each regression tree performs linear regression, a
technique which determines the linear function that best describes
the relationship between a dependent variable and predictor
variables based on minimizing the sum of squares of model
residuals. Each regression tree is measured for predictability by
using the remaining sample as an ‘‘out-of-bag’’ (OOB) testing
sample (Figure S1); each predictor is assigned an importance
Biomarker Predictors of Fat Distribution
PLOS ONE | www.plosone.org 2 August 2012 | Volume 7 | Issue 8 | e43502
measure based on this cross-validation [15,16]. The Random
Forest method provides a summary of the importance of
predictors across the multiple regression trees and, thus, is suitable
for multicollinear predictors, as it grows each tree with only a
subset of all predictors and ranks correlated predictors with similar
importance in later cross-validation [16]. It has been widely utilized
in the prediction of complex biological pathways [18] and cancer
risk [19].
All predictor and outcome variables, other than ethnicity, were
continuous – percent liver fat was natural-log transformed to meet
model assumptions. Among the 58 biomarkers, highly correlated
markers (r.0.8) were consolidated in order to keep only one
marker in each correlated cluster with the highest correlation with
adiposity outcomes. As the result, 48 biomarkers were included in
the final data analysis. For example, leptin-adiponectin ratio was
chosen over adiponectin (rho= 20.87), insulin over Homeostatic
Model Assessment of beta-cell function (HOMA-beta; rho= 0.80)
or HOMA of insulin resistance (HOMA-IR; rho= 0.99), and total
cholesterol over low-density lipoprotein cholesterol (LDL;
rho= 0.91), due to their respective high correlations (all
p’s,.0001). Random Forest prediction models for each adiposity
outcome included: (1) anthropometric variables (BMI, WC,
WHR), age and ethnicity; (2) 48 biomarkers, age, ethnicity and
key covariates; (3) only the top 5 most important predictors from
the biomarker model (2); and (4) top 5 predictors (from model 2),
anthropometric variables (BMI, WC, WHR), age and ethnicity.
The key covariates that were tested in model (3) included information
on smoking status (never vs. former, pack-years of cigarette
smoking), education, use of medications (estrogen, statins, aspirin)
and dietary supplements, and number of children. Age, ethnicity
and the key covariates were selected because they may confound
the association between biomarkers and body fat distribution but,
as with all other variables in the model, were not retained if they
did not show important predictive ability. Because of the limited
sample size, a stratified sampling approach was used for each tree
so that there were no imbalances between the splits in the
distributions of all adiposity variables by age, BMI and WHR (t-
test p.0.50). For each analysis, 500 regression trees were fit to the
training data of 2/3 of the sample, with each tree using a subset of
all available predictors. Two measures of predictability were
created in each iteration. An importance score for each predictor was
created from each cross-validation step using the 1/3 OOB testing
sample, defined as the percent increase in the mean square error
upon random permutation of the given predictor. The R2 gives the
proportion of variability in the dependent variable that is
accounted by the given model in the test data. Subsequently, the
top 20 most ‘‘important’’ predictors were plotted and the top 5
most important predictors selected for each adiposity outcome
based on the measure of predictability. All statistical analyses were
performed using the R statistical computing environment, v2.12.1
(R Core Development Team, 2010) and SAS v9.3 (SAS Institute,
Cary, NC). Random Forest modeling was implemented using the
randomForest package for R (Liaw & Wiener 2002).
Results
Table 1 describes the participant characteristics. Since the
recruitment balanced the sample by ethnicity and BMI categories
and applied an upper BMI limit of 40 kg/m2, participants’ BMI
ranged from normal-weight to Class II obesity (18.8–39.6 kg/m2)
Table 1. Characteristics of participating women.
N with
available data* Mean (standard deviation) or N (%) Range
Age, yrs 60 63.4 (1.37) 60.9–65.8
Ethnicity, n (%) 60
Caucasian American 30 (50%) –
Japanese American 30 (50%) –
Smoking history*, n (%) 60
Never 37 (62%) –
Former 23 (38%) –
Hormone treatment, % current use 60 6 (10%) –
Lipid-lowering medications, % current use 60 22 (37%) –
Dietary supplement, % current use 60 51 (85%) –
Body Mass Index (BMI), kg/m2 60 26.7 (4.9) 18.8–39.6
Obese (BMI $30 kg/m2), n (%) 60 14 (23%)
Waist circumference (WC), cm 60 94.9 (14.4) 70.3–134.9
Waist-hip ratio (WHR) 60 0.93 (0.08) 0.78–1.10
Abdominal obesity (WC.88 cm or WHR.0.85) 60 53 (88%) –
Total fat mass, kg 60 27.2 (9.2) 11.1–53.5
Trunk-to-periphery fat ratio 60 1.26 (0.34) 0.67–2.35
Visceral fat area, mm2 48 138.2 (93.9) 16.3–50.1
Subcutaneous fat area, mm2 48 19.5 (98.9) 69.3–553.1
Liver fat, % 48 6.2 (5.6) 1.5–20.9
Fatty liver (.5.5% liver fat) 48 17 (35%) –
*Current smokers were excluded from the study. 12 women did not participate in the MRI studies.
doi:10.1371/journal.pone.0043502.t001
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and was distributed similarly between Caucasian and Japanese
American women [10]. Also, the mean total fat mass among these
women (27 kg), partially due to the truncated BMI range at
recruitment, was lower than that reported in a national survey for
mostly white women of similar ages (< 32 kg/m2) [20].
Nevertheless, a majority of these healthy, non-diabetic women
(88%) had abdominal obesity (WC.88 cm or WHR.0.85), and a
substantial fraction (35%) also had fatty liver (liver fat.5.5%;
[21]).
Figure 1 illustrates the Random Forest plots for predicting
total, abdominal, visceral and liver fat, based on biomarkers as well
as age, ethnicity, and key covariates, and without the anthropo-
metric indicators (model 3). Predictors selected from the training
data sets are listed in the order of ‘‘importance’’ for up to 20
predictors. Based on the test data sets, these biomarkers explained
70%, 51%, 47% and 44% of the variance in total, abdominal,
visceral and liver fat, respectively (Table 2). The top 5 predictors
for each adiposity outcome in the testing data set were identical,
and in a mostly identical order, as the top 5 predictors in the
training data set.
Table 2 presents the results from various prediction models. For
total fat, the Random Forest model based on anthropometry, age
and ethnicity explained most of the variation (R2= 0.85). Random
Forest of 46 biomarkers and covariates (age, ethnicity, smoking,
medication, supplement and parity), without anthropometry,
provided a good but lower prediction (R2 = 0.70) than the
prediction from the anthropometry model. The top 5 most
important predictors alone (leptin, leptin-adiponectin ratio [LAR],
free estradiol, plasminogen activator inhibitor-1 [PAI1], and
alanine transaminase [ALT]) predicted 69% of the variation.
However, Random Forest prediction of total body fat mass based
on these 5 top predictors and anthropometry combined showed
the best prediction (R2= 0.91).
Unlike total fat mass, the prediction of abdominal fat (TPFR)
was similar by anthropometry alone (R2 = 0.53) or by biomarkers
alone (R2 = 0.51), although the R2 was attenuated when consid-
ering only the top 5 predictors (25(OH)-vitamin D3, insulin-like
growth factor binding protein-1 [IGFBP1], uric acid, soluble leptin
receptor [sLEPR], Coenzyme Q10 [CoQ10]; R2 = 0.35). Adding
the top 5 biomarkers to BMI and the waist measures improved
somewhat the prediction of abdominal fat (R2= 0.58).
The prediction of visceral fat obtained from the biomarkers
(R2= 0.47) was improved when considering only the top 5
biomarkers (leptin, C-reactive protein [CRP], LAR, lycopene,
vitamin D3; R
2= 0.58). Adding the anthropometric variables to
the biomarkers further improved the prediction (R2 = 0.68) and
performed better than the anthropometry-only model (R2 = 0.65).
Liver fat was predicted 1.5-fold better by the biomarkers
(R2= 0.44) than by anthropometric variables alone (R2 = 0.29),
with the top 5 predictors from the biomarker model being insulin,
sex hormone binding globulin [SHBG], LAR, alpha-tocopherol,
and PAI1 (R2= 0.42). Adding BMI and waist size variables to the
biomarker model only improved the prediction slightly (R2 = 0.44).
Discussion
These prediction analyses of measured total and regional fat
mass confirmed that BMI, based on weight and height, and waist
size measurements together predict total body fat very well
(R2= 85%). However, we found that measures of abdominal and
intra-abdominal (visceral and liver) fat were predicted less
optimally by these anthropometric variables and that the addition
of adiposity-associated biomarkers improved their predictions.
About half of the variation in abdominal adiposity was predicted
by anthropometry, with the prediction of this variability further
improved by adding the top 5 predictors from the Random Forest
biomarker model (R2= 0.53 to 0.58). The prediction of visceral fat
also improved slightly (R2 = 0.65 to 0.68) by adding the top 5
biomarker predictors. The largest contribution from the biomark-
er model was observed for the prediction of liver fat, for which R2
increased from 29% with the anthropometry model to 44% with
the model that also included the top 5 biomarkers. Blood
adipokines (leptin, leptin-adiponectin ratio, sLEPR, PAI1) con-
tributed to the prediction of both total and regional fat. Other top
predictors included markers of insulin resistance and the IGF
pathway (insulin, IGFBP1, uric acid), sex hormones (free estradiol,
SHBG), lipid-soluble micronutrients (vitamin D3, lycopene,
CoQ10, alpha-tocopherol) and markers of inflammation (CRP).
It is well established that adipose tissues are active endocrine
organs, with each regional depot having intrinsic secretory profiles
[22–24]. Thus, blood concentrations of depot-specific adipocyte-
derived biomarkers and their metabolites may reflect relative body
fat distribution and also contribute to associated metabolic risks.
Metabolic syndrome has been associated more with abdominal fat
than total or gluteofemoral fat [25,26], and more with visceral fat
compared to abdominal subcutaneous fat [27–29]. Accordingly, in
past studies, certain circulatory markers have shown a strong
association with visceral fat specifically (Table S1), including low
blood levels of adiponectin [30–32] and SHBG [33], and high
levels of PAI1 [34], visfatin [35], systemic inflammatory markers
[36], insulin [37] and free estradiol [38]. Also, liver fat has been
associated with blood levels of liver enzymes [39,40], insulin and
sLEPR [41], adiponectin [42], PAI1 [43], fetuin A [44], retinol
binding protein-4 (RBP4) [45,46], and free fatty acids [47]. Our
study included most of these biomarkers associated with regional
adiposity.
There have been few published studies that have attempted to
optimally predict body composition with a comprehensive list of
biomarkers. In a study of 56 middle-aged and 20 older adults who
were healthy but overweight, 124 proteins in fasting blood
analyzed with a Luminex multiplex assay were tested for their
prediction of BMI using Random Forest modeling [8]. Similar to
our study, the candidate markers were selected a priori, based on
their association with chronic diseases, inflammation, endothelial
function and metabolic signaling. BMI was best predicted,
positively, by leptin, complement 3 (C3), CRP, amyloid P and
vascular endothelial growth factor, and, negatively, by IL-3, IL-13
and apolipoprotein A1. In another study of 20 postmenopausal
women, DXA-based percent lean body mass was predicted by
fasting blood levels of 90 cytokines analyzed with a Luminex
multiplex assay [48]. Random Forest modeling identified 7 top
predictors of percent lean mass (serum leptin, adiponectin, insulin,
C3, amyloid P, growth hormone, eotaxin) and discriminated high
vs. low lean mass groups with less error (mean error = 8.1%,
SD=5.0%) compared to an alternative Recursive Partitioning
model (mean error = 11.9%, SD=8.5%).
Our findings support the contention that adding key biomarkers
to usual anthropometric variables may enhance the prediction of
body fat distribution patterns when reference imaging-based
methods are not practical, such as typically in large epidemiologic
studies. Past studies that compared anthropometric measures to
imaging of fat topography observed a good correlation between
anthropometry and total fat mass [49] but detected lower
correlations for intra-abdominal fat distribution [6,7]. Our study
results are consistent with this literature.
Certain biomarkers performed far better than others in
predicting specific adiposity, such as leptin for total fat, lycopene,
leptin-adiponectin ratio and leptin for visceral fat, and insulin and
Biomarker Predictors of Fat Distribution
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SHBG for liver fat (Figure 1). We did not observe one or two
predominantly strong predictors for abdominal fat like we did for
the other adiposity measures. Leptin, a well-established indicator
of total adiposity, also predicted visceral fat, together with leptin-
adiponectin ratio, which may independently reflect leptin resis-
tance due to excess intra-abdominal adiposity [50]. Insulin
resistance markers (insulin, HOMA-IR, HOMA-beta) were
consistently among the most important predictors of visceral fat
and liver fat, although we included only insulin in the final model
due to their high correlations. These results are consistent with the
notion that visceral fat carries a greater metabolic risk than
subcutaneous fat by inducing fatty acid drainage into the liver
Figure 1. Random Forest models for predicting adiposity. Total, abdominal (trunk-to-periphery fat ratio or TPFR), visceral and hepatic
adiposity measurements were predicted to various extent by a number of blood biomarkers, as well as by demographic (age, ethnicity, education)
and key lifestyle variables (smoking, medication use, supplement use, parity), without anthropometric variables. Predictors were ranked by the
importance score, which was based on percent increase in mean square error upon random permutation of the given predictor. The figure shows the
top 20 predictors for each adiposity measure. (Abbreviations: BMI [body mass index], %incMSE (percent increase in mean square error), RF [Random
Forest]; see Table S1 for the full names of the biomarkers).
doi:10.1371/journal.pone.0043502.g001
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through the portal venous system, which then may impair insulin/
glucose homeostasis [51–53]. Endogenous synthesis of estrogen
from androstenedione in adipocytes is known to be particularly
active in the subcutaneous adipose tissue, whereas visceral fat and
subsequent increase in liver fat may interfere with the production
of SHBG [54]. This is also consistent with our findings, where
blood levels of bioactive free estradiol were shown to predict total
adiposity (mostly subcutaneous fat) and SHBG predicted hepatic
adiposity.
CRP ranked high for predicting visceral adiposity. However, in
contrast to previous studies [26,55], other common markers of
systemic inflammation were either mostly undetectable (TNFa) or
showed only modest to low predictive ability for total adiposity
(IL6). This may be because our study participants were mostly
healthy adults who were non-diabetic and without overt low-grade
inflammation. Lipid-soluble micronutrients, especially D vitamers,
also showed prediction capacity for abdominal, visceral and
hepatic adiposity, as noted before [56,57].
A key strength of the present study is the implementation of
Random Forest modeling. The use of stepwise linear regression to
screen biomarkers resulted in over-fitting of the training data
(leading to many predictors in the final model and a R2.95%),
with a low predictive R2 in the testing data, in our analysis (data
not shown), as well as in past studies [58]. The tree-based Random
Forest modeling also allowed the incorporation of potentially
important interactions among predictors. This is the first time that
this analytic approach was used to predict detailed, imaging-based
regional body fat measurements. The study limitations include a
relatively small sample size and the possibility that potential
confounders were not accounted for. Also, there may be other (as
yet unidentified) biomarkers that could substantially improve the
predictions. Replications in larger datasets are warranted,
especially to compare the prediction performance of biomarkers
in men and across ethnic groups with varying body fat distribution.
In this sample of Caucasian and Japanese American women,
ethnicity was an important determinant of fat distribution [10].
Interestingly, it did not remain an important predictor after
accounting for anthropometry and the biomarker predictors.
In summary, we provide preliminary evidence that supports the
utility of measuring key blood biomarkers to improve the
performance of usual anthropometric variables in predicting
abdominal, visceral and liver fat. Discovery of additional
biomarker predictors and generalization of this research to other
populations may allow for the development of accurate prediction
models for specific body fat compartments. Such prediction
equations may be very useful in predicting risk of obesity-
associated diseases at the individual and population levels.
Supporting Information
Figure S1 Diagram of Random Forest modeling. Random
Forest takes an ensemble approach to create and summarize
multiple regression trees. For this study, each regression tree
performed linear regression of an adiposity variable of interest on a
random subset of all available predictors in a random bootstrap
subsample of all women. Each regression tree is then measured for
predictability of the given linear regression model by applying it to
the remaining sample as an out-of-bag testing sample. Each
predictor is assigned a predictability measure (‘‘importance’’)
based on this cross-validation, which is summarized across
multiple regression trees.
(DOC)
Table S1 Measured and derived biomarkers considered for
Random Forest (RF) prediction of body fat distribution and
supporting evidence.
(DOC)
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Table 2. Prediction of body fat content and distribution by anthropometry and biomarkers.
Random Forest Model Prediction in Independent Testing Subset of Data, R2
(1) BMI, WC, WHR,
age, ethnicity
(2) Biomarkers, age,
ethnicity, key
covariates* (3) Top 5 important predictors*
(4) Top 5 predictors, BMI, WC,
WHR,
age, ethnicity
R2 Predictors
Total fat mass (kg) 0.85 0.70 0.69 leptin, LAR, free estradiol, PAI1, ALT 0.91
Trunk-periphery fat ratio
(TPFR)
0.53 0.51 0.35 25(OH)-vitamin D3, IGFBP1, uric acid,
sLEPR, CoQ10
0.58
Visceral fat area (mm2) 0.65 0.47 0.58 leptin, CRP, LAR, lycopene, vitamin D3 0.68
% Liver fat (log-transformed) 0.29 0.44 0.42 insulin, SHBG, LAR, alpha-tocopherol,
PAI1
0.44
*Model (2) included all biomarkers, age, ethnicity, and key covariates, including smoking status (never vs. former, pack-years of cigarette smoking), education, use of
medications (estrogen, statins, aspirin) and dietary supplements, and number of children. Model (3) shows the top 5 predictors from Model (2).
Abbreviations: IGFBP1 (insulin-like growth factor binding protein 1); LAR (leptin to high-molecular-weight adiponectin ratio); PAI1 (plasminogen activator inhibitor-1);
SHBG (sex hormone binding globulin); sLEPR (soluble leptin receptor).
doi:10.1371/journal.pone.0043502.t002
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